Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/94460
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cenciarini, Marta | - |
dc.contributor.author | Valentino, Mario | - |
dc.contributor.author | Belia, Silvia | - |
dc.contributor.author | Sforna, Luigi | - |
dc.contributor.author | Rosa, Paolo | - |
dc.contributor.author | Ronchetti, Simona | - |
dc.contributor.author | D’Adamo, Maria Cristina | - |
dc.contributor.author | Pessia, Mauro | - |
dc.date.accessioned | 2022-04-26T15:16:38Z | - |
dc.date.available | 2022-04-26T15:16:38Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Cenciarini, M., Valentino, M., Belia, S., Sforna, L., Rosa, P., Ronchetti, S.,… Pessia, M. (2021). Dexamethasone in Glioblastoma multiforme therapy : mechanisms and controversies. In D. Boison ( Eds.), Brain disease mechanisms - editor’s picks 2021 (pp. 43-55). Lausanne: Frontiers Research Foundation. | en_GB |
dc.identifier.uri | https://www.um.edu.mt/library/oar/handle/123456789/94460 | - |
dc.description.abstract | Glioblastoma multiforme (GBM) is the most common and malignant of the glial tumors. The world-wide estimates of new cases and deaths annually are remarkable, making GBM a crucial public health issue. Despite the combination of radical surgery, radio and chemotherapy prognosis is extremely poor (median survival is approximately 1 year). Thus, current therapeutic interventions are highly unsatisfactory. For many years, GBM-induced brain oedema and inflammation have been widely treated with dexamethasone (DEX), a synthetic glucocorticoid (GC). A number of studies have reported that DEX also inhibits GBM cell proliferation and migration. Nevertheless, recent controversial results provided by different laboratories have challenged the widely accepted dogma concerning DEX therapy for GBM. Here, we have reviewed the main clinical features and genetic and epigenetic abnormalities underlying GBM. Finally, we analyzed current notions and concerns related to DEX effects on cerebral oedema, cancer cell proliferation and migration and clinical outcome. | en_GB |
dc.language.iso | en | en_GB |
dc.publisher | Frontiers Research Foundation | en_GB |
dc.rights | info:eu-repo/semantics/openAccess | en_GB |
dc.subject | Glioblastoma multiforme | en_GB |
dc.subject | Nervous system -- Diseases | en_GB |
dc.subject | Dexaminidae | en_GB |
dc.subject | Pharmacogenomics | en_GB |
dc.title | Dexamethasone in Glioblastoma multiforme therapy : mechanisms and controversies | en_GB |
dc.title.alternative | Brain disease mechanisms - editor’s picks 2021 | en_GB |
dc.type | bookPart | en_GB |
dc.rights.holder | The copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder. | en_GB |
dc.description.reviewed | peer-reviewed | en_GB |
dc.identifier.doi | 10.3389/978-2-88971-063-8 | - |
dc.publication.title | Frontiers in Molecular Neuroscience | en_GB |
Appears in Collections: | Scholarly Works - FacM&SPB |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Dexamethasone_in_Glioblastoma_multiforme_therapy_mechanisms_and_controversies_2021.pdf | 1.3 MB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.